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Aim: DNA methylation is the best known epigenetic mark. Cancer and other 
pathologies show an altered DNA methylome. However, delivering complete DNA 
methylation maps is compromised by the price and labor-intensive interpretation 
of single nucleotide methods. Material & methods: Following the success of the 
HumanMethylation450 BeadChip (Infinium) methylation microarray (450K), we report 
the technical and biological validation of the newly developed MethylationEPIC 
BeadChip (Infinium) microarray that covers over 850,000 CpG methylation sites 
(850K). The 850K microarray contains >90% of the 450K sites, but adds 333,265 
CpGs located in enhancer regions identified by the ENCODE and FANTOM5 projects. 
Results & conclusion: The 850K array demonstrates high reproducibility at the 450K 
CpG sites, is consistent among technical replicates, is reliable in the matched study of 
fresh frozen versus formalin-fixed paraffin-embeded samples and is also useful for 
5-hydroxymethylcytosine. These results highlight the value of the MethylationEPIC 
BeadChip as a useful tool for the analysis of the DNA methylation profile of the 
human genome.
First draft submitted: 18 November 2015; Accepted for publication: 2 December 2015; 
Published online: 17 December 2015
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DNA methylation is the most recognized 
epigenetic mark in the human genome. The 
presence of 5-methylcytosine is usually asso-
ciated with the transcriptional silencing of the 
underlying DNA sequence, while its absence 
permits expression if the right transcription 
factors are present. DNA methylation plays 
a major role in the determination of tissue-
specific expression of genes, the silencing 
of endoparasitic sequences, chromosomal 
stability, parental-determined monoallelic 
expression (imprinting) and X-chromosome 
inactivation in females [1]. These highly regu-
lated DNA methylation patterns are altered 
in human disorders, particularly undergo-
ing a massive distortion in cancer cells [2–5]. 
The aberrant landscape of DNA methyla-
tion in tumors is very complex; however, two 
features are striking: promoter CpG island 
hypermethylation associated inactivation 
of coding and noncoding tumor suppressor 
genes as well as an overall hypomethylation 
of the cancer genome, as has been recently 
shown by the existence of DNA hypometh-
ylation blocks. Our understanding of the 
DNA methylation patterns in human cancer 
has clinical relevance in two forms: firstly it 
provides biomarkers to complement the clas-
sical diagnosis and prognosis indicators that 
predict chemosensitivity to anticancer drugs; 
and secondly, by itself being a target for new 
drugs, such as those that target DNA meth-
yltransferases in the context of hematological 
malignancies [6–8]. Importantly, the relevance 
of DNA methylation in cancer has fostered 
studies in other prevalent human diseases, 
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such as dementia and cardiovascular pathologies, with 
focus expanding from DNA methylation events that 
occur in the affected tissue, as well as to the constitu-
tive DNA methylation variants that can represent risk 
factors for a particular disease, using epigenetic-wide 
association studies (EWAS) [9,10]. In this regard, it is 
imperative to have robust and accessible techniques for 
acquiring extensive DNA methylation profiles from 
distinct cells and tissue types such that the resulting 
profiles are interchangeable and permit the easy data 
mining and comparison of results among scientists 
with varied interests in laboratories across the world.
Bisulfite genomic sequencing of multiple clones is 
the ‘gold standard’ for the determination of the CpG 
methylation status of a DNA sequence. This strategy 
combined now with deep-sequencing chemistry, has 
allowed the completion of whole-genome bisulfite 
sequences for the human genome [11–15]. However, 
obtaining full human DNA methylomes requires 
a large effort in time and budget and thus are still 
scarce and associated with a high level of ultraspecial-
ization. Perfectly annotated DNA microarrays with 
great genomic coverage are required to detect SNPs 
genome-wide and are used extensively in genome-
wide asssociation studies (GWAS). User-friendly DNA 
methylation microarrays have been modeled after 
these and now have become widely adopted. Among 
these, the Illumina Infinium HumanMethylation450 
BeadChip 450,000 CpG site platform (450K; Illumina 
Inc., CA, USA) for DNA methylation studies [16] has 
reached a predominant place in the market and the sci-
entific arena, being not only the platform selected for 
The Cancer Genome Atlas (TCGA) studies [17], but 
also for numerous studies interrogating tumors out-
side these consortiums [18,19], the aging process [13] or 
interindividual variability [20]. The versatility of the 
described microarray has also been shown by its capac-
ity to determine 5-methylcytosine DNA patterns from 
formalin-fixed paraffin-embedded samples [21] and 
for the recently identified 5-hydroxymethylcytosine 
mark [22,23].
However, there is room for improvement. This is 
particularly true for sequences, such as enhancers, 
that impact the transcription while lying distal to 
the transcription start site [24]. The existence of chro-
mosomal territories in the interphase nucleus is now 
widely accepted, as is the looping and contact of DNA 
elements interspersed at great genomic distance. Such 
loops are of great relevance for transcription given 
that they afford the proximity and communication 
between gene promoters and their enhancers [25] or 
super enhancers [26,27]. The implementation of chroma-
tin conformation capture (3C)-based methods associ-
ated with deep sequencing, such as 4C [28] or the Hi-C 
methodology [29], have greatly expanded our knowledge 
in this area. Given that methylation status can affect 
the binding of cognate transcription factors [30], it is 
highly probable that DNA methylation differences in 
enhancer sequences exert a major role in cell and tissue 
functionality and that altered profiles could contrib-
ute to human diseases. The launch of a new 853,307 
CpG (850K) site platform for DNA methylation stud-
ies (MethylationEPIC BeadChip Infinium) appears to 
be a promising tool to address these issues, as it incor-
porates 333,265 CpG sites located in enhancer regions 
identified by the ENCODE [31,32] and FANTOM5 [33] 
projects. Herein, we have validated the 850K DNA 
methylation microarray from a biological and techni-
cal standpoint. Our results show that the novel plat-
form is able to reproduce the 450K DNA methylation 
data in a reliable manner, and is also useful in the con-
text of formalin-fixed paraffin-embedded samples as 
well as in the assessment of 5-hydroxymethylcytosine. 
Thus, the 850K DNA methylation microarray will be 
a valuable tool to understand the relevance of enhancer 
DNA methylation to human cell biology and an essen-
tial accompanying partner for the ongoing and future 
international genomic projects to study disease onset.
Results & discussion
Genomic & functional classification of the over 
850,000 cytosine sites in the human DNA
The widely used 450K DNA Methylation array (Infin-
ium HumanMethylation450 BeadChip) includes 
485,577 cytosine positions in human DNA distributed 
among all 22 autosomal and 1 sex chromosome pair. 
When correlated to RNA transcripts, 74.4% of CpGs 
correspond to coding messenger RNA genes, 0.85% 
are associated to noncoding RNAs (miRNAs and long 
noncoding RNAs) and 24.6% sites do not possess 
an associated transcript. Analysis of genomic distri-
bution shows 30.9% of the sites are in CpG islands, 
23% in CpG shores (sequences 2 kb upstream and 
downstream from CpG island), 9.7% in CpG shelves 
(sequences 2 kb upstream and downstream from shore 
regions) and 36.3% are located outside these regions 
(‘open sea’). Following a functional classification, 41% 
of the CpGs are located in proximal promoters (CpG 
sites located within 200 bp or 1500 bp upstream of 
transcription start sites, exon 1 and in 5´ UTRs), 3.2% 
correspond to 3´UTRs, 30.9% to gene bodies and 
24.6% to intergenic regions. A carefully annotated 
description of the 450K DNA methylation microarray 
has been previously published [16].
The recently developed MethylationEPIC BeadChip 
Infinium microarray interrogates the methylation status 
of 853,307 CpG sites. There are 439,562 CpGs from 
the 482,421 CpGs included in the 450K microarray 
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Figure 1. Venn diagram showing the degree of 
CpG overlapping (yellow) between the Infinium 
HumanMethylation450 BeadChip (450K; red) and the 
MethylationEPIC BeadChip (850K; green) microarrays.
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(91.1%), that are also present in the 850K DNA meth-
ylation microarray. The complete list of CpGs shared 
by both microarrays is shown in Supplementary Table 1. 
The 42,076 CpG sites (8.9%) that were included in 
the 450K microarray that are not present in the 850K 
microarray are listed in Supplementary Table 2. Most 
importantly, the MethylationEPIC BeadChip Infin-
ium includes 413,745 new CpG sites not included in 
the 450K microarray that interrogate the DNA meth-
ylation status of other sequences of the genome, which 
are shown in Supplementary Table 3. The Methylation-
EPIC BeadChip Infinium also interrogates 2880 CNG 
(C stands for cytosine; N stands for any nucleotide; G 
stands for guanine) sites that are present in the 450K 
DNA methylation microarray (Supplementary Table 4), 
while 211 CNG sites from the 450K microarray are not 
included in the 850K platform. No new CNG sites are 
added in the EPIC platform. The 850K microarray also 
includes 59 SNP sites that are used for quality control 
processes (Supplementary Table 5). The degree of CpG 
site overlap between the 450K and the 850K DNA 
methylation microarrays is summarized in Figure 1.
The 413,745 CpG newly added positions in the 
850K microarray are localized among all 22 autosomal 
chromosomes in addition to the X and Y sex chromo-
somes (Figure 2A). Chromosome 1 harbors the most 
positions (39,087, 9.4%) and chromosome Y the fewest 
(179, 0.04%). According to the manufacturer’s tech-
nical notes, most (95.1%) of them used the Infinium 
Design II, while only 4.9% used Infinium Design I 
(Figure 2B). Following a functional classification, 
25.8% of the CpGs are located in proximal promoters 
(CpG sites located within 200 bp [5.4%] or 1500 bp 
[10.6%] upstream of transcription start sites, exon 1 
[0.4%] and in 5´ UTRs [9.4%]), 0.9% correspond to 
3´UTRs, 40% to gene bodies and 33.3% to intergenic 
regions (Figure 2C). Relative to CpG context, 5.4% of 
the sites are in CpG islands, 11.4% in CpG shores, 5% 
in CpG shelves and, most importantly, the vast major-
ity (78.2%) are located outside these regions (‘open 
sea’) (Figure 2D). The observation that the newly 
included CpGs in the 850K DNA methylation micro-
array are mainly located in sequences with poor CpG 
content, in addition to its intergenic location (33.3%), 
fits with the concept that these CpG sites were incor-
porated from the human enhancer regions provided by 
the ENCODE [31,32] and FANTOM5 [33] projects. For 
example, 4.9% of all the CpG sites are derived from a 
FANTOM5 defined enhancer (Figure 2E). With respect 
to ENCODE regulatory elements, 19.3% of the CpGs 
are located within a known transcription factor bind-
ing site identified by ChIP-Seq (Chromatin Immuno-
precipitation and Sequencing) (Figure 2F), 14.6% are 
in ‘open’ chromatin regions defined by FAIRE-Seq 
(Formaldehyde-Assisted Isolation of Regulatory Ele-
ments Sequencing) (Figure 2G) and 53.6% of the CpGs 
correspond to DNase hypersensitive regions identified 
by DNase-seq (Figure 2H).
The genomic and functional context of all the 
853,307 CpGs included in the MethylationEPIC 
BeadChip Infinium assay, including those ‘exported’ 
from the 450K microarray (439,562) with those newly 
incorporated in the 850K microarray (413,745 CpGs) 
was analyzed next in whole. All 22 autosomal chro-
mosomes in addition to the X and Y sex chromosomes 
are present, with chromosome 1 harboring the most 
positions (9.5%) and chromosome Y the fewest (0.1%) 
(Figure 3A). Considering Infinium design, most CpGs 
used Design II (83.8%), whereas 16.2% used Design I 
(Figure 3B). To quantify the possible false CpG methyl-
ation calling due to the presence of a SNP, we analyzed 
how many 850K CpG probes have an SNP within 
their last ten bases and with a Minor Allele Frequency 
(MAF) ≥5% according to the 1000 Human Genome 
Project database [34]. We observed that 8.8% of the CpG 
sites had an associated SNP with the described features 
(Supplementary Table 6). According to associated RNA 
transcripts, 623,483 CpGs (73.1%) correspond to clas-
sic coding messenger RNA genes, while 21,446 (2.5%) 
are linked to noncoding RNAs (9961 for miRNAs 
and 11,485 for long noncoding RNAs). For 229,824 
(26.9%) sites there are no annotated transcripts associ-
ated with the described CpG location. Addressing the 
issue of functional classification, 35.2% of the CpGs 
are located in proximal promoters (CpG sites located 
within 200 bp [9.4%] or 1500 bp [13.9%] upstream of 
transcription start sites, exon 1 [1.2%] and in 5´ UTRs 
[10.7%]), 1.9% correspond to 3´UTRs, 35.9% to gene 
bodies and 26.9% to intergenic regions (Figure 3C). As 
a function of CpG landmarks, 17.8% of the sites are 
10.2217/epi.15.114 Epigenomics (Epub ahead of print)
Figure 2. Genomic and functional context of the newly added 413,759 CpG sites in the MethylationEPIC BeadChip microarray 
(850K). (A) Chromosome location; (B) Infinium design chemistry (Infinium I, II); (C) UCSC gene region feature category (TSS200, 
TSS1500, 5´UTR, 1st Exon, body, 3´UTR); (D) location of the CpG relative to the CpG island (open sea, island, shore, shelf); (E) 
FANTOM5 associated enhancer regions; (F) ENCODE project annotation for transcription binding site; (G) open chromatin, and (H) 
DNase I hypersensitive regions.
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in CpG islands, 16.9% in CpG shores and 8.8% in 
CpG shelves, but most of the CpG sites (56.5%) are 
not in any of these sequences (‘open sea’) (Figure 3D). If 
we combine the two classifications described above, we 
can determine that for the 300,554 CpG sites located 
in proximal promoters, 102,892 CpGs (34.2%) are 
in CpG islands, 84,491 (28.1%) in CpG shores and 
18,393 (6.1%) in CpG shelves, while 94,778 (31.5%) 
are in other regions of the genome without any enrich-
ment of CpG content (open sea) (Figure 3). Related to 
regulatory regions, 3.2% of the CpG sites are within 
FANTOM5 described enhancer regions (Figure 3E), 
covering 36.3% of the described FANTOM5 enhanc-
ers with at least one CpG site. The included FAN-
TOM5 enhancers are within a CpG island, shelf or 
shore in 26.6% of cases, whereas the remaining 73.4% 
are outside these CpG sequence categories. In addition, 
15.6% of the CpGs are located within a known tran-
scription factor binding site (Figure 3F), 13.8% are in 
open chromatin regions (Figure 3G) (covering 38.7% 
of overlapped open chromatin regions annotated in the 
ENCODE project) and 57.4% correspond to CpGs 
within DNase I hypersensitive regions (Figure 3H). 
779 CpGs are located in defined imprinting regula-
tory sites [35,36]. Other detailed information about the 
CpGs included in the 850K array can be found at the 
manufacturer website [37].
Validation of the 850K DNA methylation 
microarray: concordance with 450K 
microarray data, same sample reproducibility, 
performance in formalin-fixed paraffin-
embeded samples, 5-hydroxymethylcytosine 
determination & clustering analysis
To prove the utility and reliability of the Infinium 
MethylationEPIC BeadChip for the analysis of DNA 
methylation, we performed five different tests. First, 
we provided a technical validation of the 850K DNA 
10.2217/epi.15.114 www.futuremedicine.com
Figure 3. Genomic and functional context of the 853,307 CpG sites in the MethylationEPIC BeadChip microarray (850K).  
(A) Chromosome location; (B) Infinium design chemistry (Infinium I, II); (C) UCSC gene region feature category (TSS200, TSS1500, 
5´UTR, 1st Exon, Body, 3´UTR); (D) location of the CpG relative to the CpG island (open sea, island, shore, shelf); (E) FANTOM5 
associated enhancer regions; (F) ENCODE project annotation for transcription binding site; (G) open chromatin and (H) DNase I 
hypersensitive regions.
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methylation microarray data by studying a primary 
renal tumor (RCC9), and comparing the obtained 
results from the well established and fully standardized 
450K platform. We observed that DNA methylation 
data obtained with the new 850K microarray was highly 
correlated with the methylation levels detected at each 
CpG site using the 450K microarray (Pearson correla-
tion coefficient r = 0.992; p ≤ 2.22e-16) (Figure 4A). We 
also performed a replication experiment by hybridizing 
twice the same sample (normal colon NC22A) to the 
850K microarray. We found that the methylation lev-
els detected at CpG sites derived from each experiment 
were highly correlated and completely interchangeable 
(Pearson correlation coefficient r = 0.997; p ≤ 2.22e-16) 
(Figure 4B). Given the excellent performance of the 
450K microarray for formalin-fixed paraffin-embedded 
(FFPE) samples [21], we wondered about the reliability 
of the 850K microarray to determine the DNA meth-
ylation patterns in this type of archival material. To 
address this issue, we hybridized to the platform the 
same DNA sample obtained from fresh tissue (primary 
renal tumor RCC9) or derived after the formalin-
fixing paraffin-embedding procedure (RCC9-FFPE). 
We observed that the methylation levels detected at 
each CpG site derived from each sample were highly 
correlated (Pearson correlation coefficient r = 0.994; 
p ≤ 2.22e-16) (Figure 4C). Cellular heterogeneity is a 
potential limitation of this part of the study, but as the 
FFPE section was close to the fresh-frozen section sig-
nificant cellular heterogeneity is not expected. We also 
sought to demonstrate that the newly developed 850K 
DNA methylation microarray was also valuable for 
the study of 5-hydroxymethylcytosine patterns, as has 
been shown for the 450K platform [22,23]. To accom-
plish this aim, we carried out oxidation of DNA puri-
fied from sorted neurons (N229), a tissue particularly 
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Figure 4.  Technical and biological validation of the 850K MethylationEPIC microarray. Comparison of methylation values from 
HumanMethylation450 and their corresponding shared CpG sites present on MethylationEPIC microarray (A) for a renal tumor sample 
(RCC9). Assay reproducibility (B) of methylation measurements when using technical replicates on a normal colon (NC22A) sample. 
Correlation plot (C) of the methylation values obtained from a FFPE sample (RCC9-FFPE) when compared with its match biopsy of the 
same tumor that was preserved as FF (RCC9). 5-hmC value representation (D), where the same sample was treated as per conventional 
bifsulfite conversion or as per oxBS. Differences on oxBS with bifsulfite conversion are due to the level of 5-hydroxymethylation, 
where the absence of 5-hmC has been modeled as a discontinue red line. Frequency of hydroxymethylaton values (E) as a result of 
subtracting the oxBS values (due to 5-mC) from the BS values (due to 5-mC + 5-hmC) for each CpG site included on the 850K array. 
5-hmC: 5-hydroxymethylation; FF: Fresh frozen; FFPE: Formalin-fixed paraffin-embedded; oxBS: Oxidative bisulfite conversion.
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enriched for 5-hydroxymethylcytosine [15,38], using the 
TrueMethyl Array Kit (Cambridge Epigenetix, Cam-
bridge, UK) where the final eluted fraction followed 
the MethylationEPIC processing according to the kit 
instructions for Infinium arrays. Using this approach, 
we were able to determine the 5´ - hydroxymethylcy-
tosine patterns in the sorted neurons (Figure 4D & E). 
The genomic distribution of 5-hydroxymethylcyto-
sine, their functional annotation and genomic feature 
enrichment are shown in Supplementary Figure 1. 
Finally, we assessed the ability of the 850K microarray 
to identify differential methylated CpG sites to allow 
for the study of various biological and biomedical 
phenomena. For this purpose, we used unsupervised 
DNA clustering on the 850K methylation data from 
tissues of varying developmental origin, such as colon 
mucosa (NC22A) and neurons (N229), and were able 
to discriminate the two normal tissues based on their 
methylation profiles (Figure 5). Overall, 1468 CpG sites 
displayed differential methylation levels with delta beta 
values higher than 66% between these two cell types 
(Figure 5 & Supplementary Table 7). If we lowered the 
threshold to a 33% delta value, 73,774 CpG sites are distinct 
between these normal tissues (Supplementary Table 8). 
For these differentially methylated CpGs, 6.2% and 
12.6% were located in FANTOM5 enhancers and open 
chromatin regions defined by ENCODE, respectively. 
Most importantly, 40.5% (at delta beta value of 66%) 
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Figure 5. Biological validation of the 850K DNA methylation microarray. (A) Differentially methylated CpG sites 
(Δβ ≥0.66 ) on MethylationEPIC BeadChip microarray from a normal colon sample (NC22A), and normal sorted 
brain neurons (N229). Heatmap representation of differentially methylated CpG sites (left) and methylation 
values distribution (right) of samples where methylation differences threshold has been denoted as a 
discontinued red line (Δβ ≥0.66), and those values considered as differentially methylated have been highlighted 
in blue. (B) Differentially methylated CpG sites (Δβ ≥0.66), among the newly added 413,759 CpG sites of the 
MethylationEPIC BeadChip microarray, for a normal colon sample (NC22A), and normal sorted brain neurons 
(N229). Heatmap representation of differentially methylated CpG sites (left) and methylation values distribution 
(right) of samples where methylation differences threshold has been denoted as a discontinued red line 
(Δβ ≥0.66), and those values considered as differentially methylated have been highlighted in blue.
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(Figure 5 & Supplementary Table 9) and 55.6% (with 
delta beta value of 33%) (Supplementary Table 10) of 
these differentially methylated sites corresponded to 
the newly incorporated CpGs in the 850K, a fraction 
that due to its enrichment in enhancer sequences could 
represent a powerful tool to dissect cellular and tis-
sue lineages among different experimental conditions 
and clinical entities. The complete 850K and 450K 
data from all the described samples are available for 
download from NCBI GEO [39].
Materials & methods
Samples
Samples included in the study were all from human 
origin including a primary normal colon (NC22A) 
that was hybridized twice to validate technical repro-
ducibility, primary sorted neurons (N229), as well as 
a biopsy of a renal cancer (RCC9) which was divided 
in two pieces, one was stored as fresh-frozen (FF) tis-
sue embedded in optimal cutting temperature (OCT) 
compound stored at -80°C, while the other piece was 
formalin-fixed for 8 h followed by paraffin- embedding 
(FFPE) and stored at room temperature (RCC9-
FFPE). The corresponding Institutional Review Board 
approved the use of the described samples.
DNA extraction
All samples were extracted using column-based DNA 
extraction method (FFPE, E.Z.N.A. FFPE DNA kit, 
Omega Bio-Tek Inc., GA, USA; FF, DNeasy Blood & 
Tissue Kit; Qiagen, Hilden, Germany) following manu-
facturer’s instructions. All DNA samples were treated 
with RNaseA for 1 h at 45ºC, quantified by the fluo-
rometric method (Quant-iT PicoGreen dsDNA Assay, 
Life Technologies, CA, USA), and assessed for purity 
by NanoDrop (Thermo Scientific, MA, USA) 260/280 
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and 260/230 ratio measurements. DNA integrity of 
FF samples was checked by electrophoresis in a 1.3% 
agarose gel.
Quality check of FFPE DNAs
All DNAs from FFPE blocks were checked for their 
suitability for FFPE restoration, as indicated by the 
Infinium HD FFPE QC Assay (Illumina Inc.), by per-
forming a quantitative PCR with 2 ng of FFPE DNA. 
ΔC
q
 was calculated by subtracting the average value of 
C
q
 of the interrogated sample from the C
q
 value of a 
standard provided by the manufacturer. All FFPE sam-
ples had a ΔC
q
 <5, which is the recommended threshold 
for suitability for FFPE restoration.
Hydroxymethylation
Site-specific oxidation was carried out on 1 μg of gDNA 
of the sorted neurons in order to convert 5-hydroxy-
methyl cytosines (5-hmC) into its formyl derivative 
5-formylcytosine (5-fC) [22] using TrueMethyl Array 
Kit (Cambridge Epigenetix) following manufacturer’s 
instructions. Briefly, DNA was cleaned using provided 
magnetic beads and divided into two aliquots. Both ali-
quots were denatured, and 1 μl of oxidant solution was 
added to one of the aliquots (Ox-BS) while the other one 
(BS) underwent a mock-up oxidation process by adding 
1 μl of ultrapure H
2
0. After incubating both aliquots at 
40°C for 30 min, and centrifuging to eliminate precipi-
tates, a bisulfite conversion reaction was performed with 
the supernatant using supplied reagents. Desulfonation 
and cleanup process were applied using provided reagents 
before eluting the DNA with 10 μl of elution buffer. The 
eluate was then transferred directly to MethylationEPIC 
processing following kit instructions for Infinium arrays.
Bisulfite conversion
Three hundred nanograms of FFPE DNA, or 600 ng of 
FF DNA were randomly distributed on a 96-well plate, 
and processed using the EZ-96 DNA Methylation 
kit (Zymo Research Corp., CA, USA) following the 
manufacturer’s recommendations for Infinium assays.
FFPE restoration
Bisulfite-converted DNA (bs-DNA) from FFPE sam-
ples was processed as previously described [21]. The 
DNA was denatured with NaOH for 10 min at room 
temperature. An 1-h reaction at 37°C was then per-
formed with PPR (Primer Pre Restore) reagent and 
AMR (Amplification Mix Restore reagent) reagents 
supplied by the kit manufacturer, in which DNA repair 
is accomplished. DNA was cleaned with a ZR-96 DNA 
Clean & Concentrator-5 kit (Zymo Research Corp.) 
and eluted in 13 μl of ERB. Cleaned DNA was then 
denatured for 2 min at 95°C, followed by ligation incu-
bation at 37°C for 1 h with RST and CMM reagents. 
The resulting material was cleaned with ZR-96 DNA 
Clean & Concentrator-5 kit (Zymo Research Corp.) 
and eluted in 10 μl of DiH
2
0.
Array hybridization
MethylationEPIC beadarray shares the Infinium HD 
chemistry Assay (Illumina Inc.) used to interrogated 
the cytosine markers with HumanMethylation450 
beadchip. Thus, the applicable protocol for Methyl-
ationEPIC is the same as for HumanMethylation450, 
which is the Infinium HD Methylation Assay Protocol.
Eight microliter of restored FFPE bs-DNA, 4 μl of 
FF bs-DNA or 7 μl of samples that underwent oxida-
tion protocol were used to process them following the 
Illumina Infinium HD Methylation Assay Protocol, as 
previously described [16]. The only difference was that 
the hybridization volume of processed sample used to 
load the microarray was 26 μl instead of the 15 μl used 
in the case of HumanMethylation450.
Data normalization & statistics
The resulting raw data (IDATs) were normalized 
(control normalization) and background corrected 
using the methylation module (1.9.0) available on 
GenomeStudio (v2011.1) software. All statistical cal-
culation were performed under R statistical environ-
ment (v.3.1.1). The complete 850K and 450K data 
from all the described samples are available for down-
load from NCBI GEO [39].
Marker classification
CpG markers present on MethylationEPIC were clas-
sified based on its chromosome location, the infinium 
chemistry used to interrogate the marker (Infinium I, 
Infinium II) and the feature category gene region as 
per UCSC annotation (TSS200, TSS1500, 5´UTR, 
1st Exon, Body, 3´UTR). Related to this last clas-
sification, categories included TSS200 as the region 
between 0 and 200 bases upstream from the tran-
scriptional start site (TSS); TSS1500 category, 
200–1500 bases upstream TSS; 5´UTR included the 
region between the TSS and the start site (ATG); 
CpGs within the first exon of a gene were consid-
ered as 1st Exon category; CpGs downstream the 
first exon including intronic regions until the stop 
codon, were classified as gene body; CpGs located 
downstream the stop codon until the poly A signal 
were considered as 3´UTR; and CpGs that were not 
classified in any of the previous categories were anno-
tated as intergenic. When multiple genes or TSS were 
associated with a CpG site, category prioritization 
was applied following a 5 -´prime to 3 -´prime criteria 
(TSS200 > TSS1500 > 5´UTR > 1st Exon > Body > 
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3´UTR > Intergenic). Additional criteria included 
the location of the marker relative to the CpG island 
(open sea, island, shore, shelf ), fantom 5-associated 
enhancer regions and regulatory regions described on 
ENCODE project [32,33] such as transcription bind-
ing site sequences, open chromatin regions and digital 
DNase I hypersensitivity clusters.
Conclusion
Our results validate the Infinium MethylationEPIC 
BeadChip (850K) as a highly reliable genomic platform 
for the study of DNA methylation patterns and levels 
in the human genome. Most importantly, in addition 
to showing great correlation with previous DNA meth-
ylation platforms, high reproducibility and suitability 
to study formalin-fixed paraffin-embeded samples 
and 5-hydroxymethylcytosine, it also represents an 
extremely valuable tool to decipher how DNA methyla-
tion changes in unexplored territories, such as enhancer 
sequences, contribute to cell homeostasis and human 
diseases.
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Executive summary
•	 5-methylcytosine is the most recognized epigenetic mark in the human genome.
•	 The obtention of full human DNA methylomes requires a large effort in time and budget.
•	 User-friendly DNA methylation microarrays, such as the Illumina Infinium HumanMethylation450 BeadChip 
(450K; Illumina Inc., CA, USA), have become widely adopted, but many potentially important regulatory CpG 
sites are not interrogated.
•	 This study investigates whether the newly developed MethylationEPIC BeadChip (850K) can be a reliable tool 
for more comprehensive DNA methylation analyses.
Results & discussion
•	 The recently developed EPIC microarray interrogates the methylation status of 853,307 CpG sites, adding 
413,745 CpG positions in comparison to the 450K.
•	 The new CpGs in the 850K microarray are enriched in regulatory regions provided by the ENCODE and 
FANTOM5 projects such as enhancers, transcription factor binding sites, ‘open’ chromatin regions and DNase I 
hypersensitive regions.
•	 DNA methylation data obtained with the new 850K microarray was highly correlated with the methylation 
levels detected using the 450K microarray.
•	 Replication experiments by hybridizing twice at 850K the same sample detected completely interchangeable 
CpG methylation values.
•	 Methylation levels detected from the same DNA sample obtained from fresh tissue or formalin-fixing paraffin-
embedding were highly correlated.
•	 The 850K array was useful to determine 5‘-hydroxymethylcytosine patterns in sorted neurons.
•	 850K data permit unsupervised DNA clustering to discriminate different biological samples.
Material & methods
•	 The samples included in the study were all from human origin including fresh-frozen and formalin-fixed 
paraffin-embedding.
•	 DNA extraction, bisulfite conversion, site-specific oxidation and array hybrydization to the 450K and 850K 
microarrays was performed according to the manufacturer instructions (Illumina Inc.).
•	 The complete 850K and 450K data are available for download from NCBI GEO.
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